Newly Nasdaq-listed BBI focused on developing differentiated therapeutics for treatment of dermatologic disorders Merger brings $60 Million in Combined Cash from Vical and R&D funding from NovaQuest Pivotal Phase 3 Clinical Trials for Brickell’s Lead Product Candidate, Sofpironium Bromide, in Patients with Axillary Hyperhidrosis to Begin Q4 2019 BOULDER, Colo., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company,...